
Who is Speaking at INVEST 2025?
The healthcare investor conference, scheduled for May 20 and 21 at the Willis Tower in Chicago, combines panel discussions, networking opportunities, and a startup pitch contest. Register today!
The healthcare investor conference, scheduled for May 20 and 21 at the Willis Tower in Chicago, combines panel discussions, networking opportunities, and a startup pitch contest. Register today!
Months into the Covid-19 pandemic, the pace of new investments for startups has picked back up. Five VCs shared what's changed and how they're working in the midst of the crisis.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
The new fund is the single largest ever raised in Michigan eclipsing the earlier $220 million Arboretum IV fund raised in 2015.
The company will use the $10 million from Blue Cross Blue Shield Venture Partners and Arboretum Ventures to add new team members who can help grow the business.
The company is preparing to announce an acquisition next month and is positioned to look for other technology companies to grow and finetune its business.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
At a recent conference in Minneapolis, a panel discussing where the best medtech startup opportunities are located gave an answer sure to please the hometown crowd: the Midwest was singled out as a great location for starting new firms. “We love the Midwest,” said Jan Garfinkle, founder and managing director of Arboretum Ventures, a venture […]
In its second wind as a company, Esperion Therapeutics (once owned by Pfizer) has just collected $33 million to continue with clinical trials of its cholesterol-lowering drug. Plymouth, Michigan-based Esperion is in phase 2 trials of ETC-1002, a once-daily oral drug designed to regulate abnormal lipid and carbohydrate metabolism without many of the side effects […]
NxThera Inc., a Shoreview, Minnesota-based startup developing a thermal vapor prostate treatment, is bringing in millions of extra investment dollars, including from a corporate partner.
NxThera Inc. has raised $2 million from the sale of equity and warrants, according to documents filed with the Securities and Exchange Commission. The startup based in St. Paul is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue.
NxThera Inc. has raised $1 million from the sale of equity and debt, according to documents filed with the Securities and Exchange Commission. The start-up, based in St. Paul, is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue. CEO Robert Paulson formerly led Restore Medical Inc., a […]
Delphinus Medical Technologies Inc. has received $8 million in funding commitments to further develop an ultrasonic breast cancer detection device that could become an alternative to mammograms. The funding means that Delphinus can finally begin the process of commercializing its SoftVue device, which has undergone about 10 years of research and development. Unlike mammography, which […]
Obstetricians, nurse-midwives and labor and delivery nurses now have a powerful — and inexpensive — tool for assessing a woman’s risk of delivering a baby too early. CerviLenz. The disposable device made by CerviLenz Inc. — a Chagrin Falls, Ohio, startup — was introduced today at the American Academy of Obstetricians and Gynecologists annual meeting […]
Dr. Brian Duncan caught the business bug as the only clinician on a team of Cleveland Clinic researchers who set out in 2004 to develop a heart-assist pump for infants with heart failure. The Clinic wooed Duncan, a pediatric heart surgeon, and his cardiac anesthesiologist wife to Cleveland in 2001. A few years later, the […]
Esperion Therapeutics Inc., a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a SEC filing. The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.